JYMed Peptide’s New Semaglutide DMF No. 041090 Listed as “Available for Reference” by the U.S. FDA JYMed Peptide recently announced that an additional Drug Master File (DMF) for its Semaglutide active pharmaceutical ingredient (API), DMF No. 041090, has successfully...
Recently, Hubei JXBio Pharmaceutical Co., Ltd. ("Hubei JXBio"), the peptide manufacturing base of Jianyuan Pharmaceuticals, received the Chemical API Marketing Approval Notification for Icatibant Acetate (Registration No.: Y20240000910) issued by the...
To Our Valued Clients, Partners, and Friends, We are pleased to announce the appointment of Dr. ZhaoBo Gao as Chief Operating Officer (COO) of JYMed Peptide. Dr. Gao brings more than 20 years of successful experience in...
Date: March 2026 | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy...
JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
A condition may be “rare,” but no person should feel invisible.At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.Today, we stand with patients, families, advocates, and...
From all of us at JYMed Peptide, we wish our customers, partners, and friends around the world a joyful Lunar New Year, filled with good health, happiness, and success. Thank you for your continued trust and collaboration. We look forward to supporting your projects...
Why Sustainable Peptide Manufacturing Is Becoming Essential in Pharma Sustainable peptide manufacturing is rapidly becoming a priority in the pharmaceutical industry. The rapid global expansion of peptide therapeutics in metabolic and chronic disease treatment is...
As part of our semaglutide program, JY MedTech has successfully completed the registration of the semaglutide active pharmaceutical ingredient (API) Korean Drug Master File (K-DMF) in South Korea. The API registration certificate has been issued by the Korean Ministry...
中文